(Q34074147)

30 July 2017

Medical management of neurocysticercosis. (English)

1 reference

30 July 2017

1 reference

5

Vera Lucia Lanchote

1 reference

30 July 2017

Osvaldo Massaiti Takayanagui

1

1 reference

30 July 2017

Newton Satoru Odashima

2

1 reference

30 July 2017

Pierina S Bonato

3

1 reference

30 July 2017

Jose Eduardo Lima

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

15 November 2011

1 reference

Expert Opinion on Pharmacotherapy

30 July 2017

1 reference

30 July 2017

12

1 reference

30 July 2017

18

1 reference

30 July 2017

2845-2856

1 reference

Magnitude of the disease burden from neurocysticercosis in a developing country

30 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

The US Centers for Disease Control and Prevention (CDC) and research and control of cysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Public health implications of cysticercosis acquired in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Deaths from cysticercosis, United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Neurocysticercosis: a review of current status and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Neurocysticercosis: updated concepts about an old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Symptomatic human neurocysticercosis--age, sex and exposure factors relating with disease heterogeneity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Taenia solium cysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Neurocysticercosis and epilepsy in developing countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Calcific neurocysticercosis and epileptogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

A prognostic classification of cerebral cysticercosis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Cognitive impairment and dementia in neurocysticercosis: a cross-sectional controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Clinical aspects of neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis. The Cysticercosis Working Group in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

New developments in the management of neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Nested PCR for specific diagnosis of Taenia solium taeniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Proposed diagnostic criteria for neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Neuro-endoscopic management of intraventricular neurocysticercosis (NCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Endoscopic management of intraventricular neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Endoscopic management of hydrocephalus due to neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Surgical management of neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Calcified cysticercotic lesions and intractable epilepsy: a cross sectional study of 512 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Treatment of neurocysticercosis: current status and future research needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Cysticercosis and epilepsy: a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Current consensus guidelines for treatment of neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Pharmacokinetic optimisation of the treatment of neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Severe forms of neurocysticercosis: treatment with albendazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Therapy for neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Short regimen of praziquantel in the treatment of single brain enhancing lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Single-day praziquantel versus 1-week albendazole for neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Optimization of the single-day praziquantel therapy for neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Mode of action of benzimidazoles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Therapy for neurocysticercosis. Comparison between albendazole and praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Large cerebral infarction during praziquantel therapy in neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Spontaneous radiographic disappearance of cerebral cysticercosis: three cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Cerebral cysticercosis: documentation of natural history with CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

High prevalence of calcified silent neurocysticercosis in a rural village of Mexico.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Effect of gender in the disposition of albendazole metabolites in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Interaction between grapefruit juice and praziquantel in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Bioavailability of praziquantel increases with concomitant administration of food

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Enantioselective analysis of albendazole sulfoxide in cerebrospinal fluid by capillary electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Evaluation of the efficacy of albendazole sulphoxide and praziquantel in combination on Taenia crassiceps cysts: in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.634801

10.1517/14656566.2011.634801

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference